Schizophrenia: Clinical Trials

3,520 trials for Schizophrenia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2322 completed, 406 unknown, 282 recruiting, 246 terminated. 1347 Not applicable, 466 Phase 3, 454 Phase 4, 450 Phase 2, 370 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable1347Completed 796, Unknown 198, Recruiting 157, Terminated 69, Not yet recruiting 68, Withdrawn 26, Active not recruiting 20, Enrolling by invitation 10, Suspended 3
Phase 3466Completed 345, Terminated 53, Recruiting 24, Unknown 24, Withdrawn 10, Not yet recruiting 6, Active not recruiting 3, Enrolling by invitation 1
Phase 4454Completed 334, Unknown 49, Terminated 38, Recruiting 15, Withdrawn 9, Not yet recruiting 8, Active not recruiting 1
Phase 2450Completed 305, Terminated 51, Recruiting 31, Unknown 23, Withdrawn 20, Not yet recruiting 10, Active not recruiting 5, Suspended 4, Enrolling by invitation 1
Phase 1370Completed 288, Terminated 23, Unknown 19, Recruiting 16, Withdrawn 9, Not yet recruiting 8, Active not recruiting 4, Suspended 3
Early Phase 127Completed 18, Unknown 4, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1

Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use
Phase 2WithdrawnUniversity of Maryland, Baltimore2050-01-012021-04-19
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
Semaglutide (SEMA), Exercise module, Anti-inflammatory diet module - Severe Mental Illness, Depression / Major Depressive Disorder
Not applicableNot yet recruitingLudwig-Maximilians - University of Munich1402028-10-012026-05-14
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2
Motion Perception Task, Sine Wave Speech Task, Volatility Task - SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Not applicableNot yet recruitingWashington University School of Medicine3252028-04-012026-11-09
Developing a Virtual Reality-assisted Intervention for Emotion Regulation Difficulties in Psychosis
MANOEUVRE therapy - Psychosis, SCHIZOPHRENIA 1 (Disorder)
Not applicableNot yet recruitingKing's College London152027-09-012026-06-03
Improving Quality of Informal Care for People With Schizophrenia
Dyadic Multicomponent Intervention (DMI), Dyadic Benefit-Finding Intervention (DBFI) - Schizophrenia
Not applicableNot yet recruitingChinese University of Hong Kong2282027-07-012026-08-25
Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia
Insightec Exablate Neuro MR-guided focused ultrasound transducer - Treatment-resistant Schizophrenia
Not applicableSuspendedNYU Langone Health32027-06-012026-04-02
Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA
Intervention via mobile application - Schizophrenia, Schizo Affective Disorder
Not applicableNot yet recruitingUniversity of Pittsburgh442027-06-012026-09-16
Prucalopride for Cognitive Functioning in Schizophrenia
Prucalopride 1 MG - Schizophrenia
Not applicableNot yet recruitingUniversity of Pittsburgh342027-05-312026-09-17
Feasibility Trial of a Parent Peer-Co-Led Caregiver Group for Pediatric Early Onset Schizophrenia Spectrum Disorders
Group Therapy, Treatment as Usual (TAU) - Schizophrenia; Psychosis
Not applicableNot yet recruitingBoston Children's Hospital202027-05-012026-10-09
Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia
Frontal gamma coherence neurofeedback, Placebo Neurofeedback - Schizophrenia, Schizoaffective
Not applicableNot yet recruitingBioSignal Solutions LLC302027-04-012026-09-24
Real-World Impact of TV-44749 in Adults With Schizophrenia
TV-44749 - Schizophrenia
Not yet recruitingTeva Branded Pharmaceutical Products R&D LLC10852027-03-302026-11-03
NST-SPARK Open-Label Phase 1 STTR (IGNITE)
NST-SPARK - Schizophrenia / Schizoaffective Disorder
Not applicableNot yet recruitingNorth Shore Therapeutics, Inc.302027-03-012026-05-18
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 3)
Active rTMS, Strong Cognitive Training, Sham rTMS - Schizophrenia
Not applicableNot yet recruitingThe University of Texas Health Science Center, Houston1202027-02-022026-11-18
LIFU Effects & Outcomes: Mechanisms Evaluating Striatal Systems Imaging (LEO MESSI)
LIFU - Schizophrenia, Auditory Hallucinations
Not applicableNot yet recruitingUniversity of California, San Francisco122027-02-012026-08-05
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingInternational University of La Rioja302027-02-012026-11-06
Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications
repetitive transcranial magnetic stimulation (rTMS) - Schizophrenia, Bipolar Disorder
Not applicableNot yet recruitingCentral South University4002027-01-012026-03-04
Shared Decision Making for Antipsychotic Medications
The Antipsychotic Medication Decision Aid (APM-DA) - Schizophrenia, Schizoaffective Disorder
Not applicableNot yet recruitingNew York State Psychiatric Institute1202027-01-012026-03-30
Brain Imaging of DSP-2342
DSP-2342 - SCHIZOPHRENIA 1 (Disorder)
Phase 2Not yet recruitingJohns Hopkins University202027-01-012026-09-30
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Xanomeline/trospium - Schizophrenia; Psychosis, Cognitive Impairment
Phase 3WithdrawnEuropean Group for Research In Schizophrenia2027-01-012026-10-30
Mechanisms and Interventions of Treatment-Resistant Schizophrenia Based on Brain Organoids
Treatment-resistant Schizophrenia
Not yet recruitingShanghai Mental Health Center102027-01-012026-11-17

Showing 20 of 3520. Sign in to see all of them.

Narrower conditions

Psychotic Disorders (1061)  ·  Bipolar Disorder (345)  ·  Mental Disorders (215)  ·  Depressive Disorder, Major (119)  ·  Depression (89)  ·  Cognitive Dysfunction (82)  ·  Hallucinations (81)  ·  Metabolic Syndrome (61)  ·  Schizophrenia, Treatment-Resistant (52)  ·  Obesity (51)  ·  Mood Disorders (50)  ·  Motor Activity (47)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (46)  ·  Cognition Disorders (44)

Broader conditions

Schizophrenia Spectrum and Other Psychotic Disorders (3474)  ·  Mental Disorders (3305)  ·  Behavior (406)  ·  Mood Disorders (375)  ·  Pathological Conditions, Signs and Symptoms (367)  ·  Bipolar and Related Disorders (343)  ·  Signs and Symptoms (298)  ·  Nervous System Diseases (274)  ·  Neurologic Manifestations (204)  ·  Nutritional and Metabolic Diseases (161)  ·  Neurobehavioral Manifestations (160)  ·  Behavioral Symptoms (152)  ·  Neurocognitive Disorders (142)  ·  Metabolic Diseases (129)  ·  Depressive Disorder (120)

Interventions

Risperidone (252)  ·  Olanzapine (178)  ·  Aripiprazole (167)  ·  Paliperidone Palmitate (121)  ·  Quetiapine Fumarate (101)  ·  Therapeutics (83)  ·  ziprasidone (73)  ·  Transcranial Direct Current Stimulation (67)  ·  Transcranial Magnetic Stimulation (58)  ·  Clozapine (57)  ·  Lurasidone Hydrochloride (45)  ·  Cognitive Behavioral Therapy (40)  ·  Haloperidol (40)  ·  Cognitive Remediation (39)  ·  Exercise (33)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. (88)  ·  AstraZeneca (78)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (73)  ·  Shanghai Mental Health Center (61)  ·  University of Maryland, Baltimore (61)  ·  Centre for Addiction and Mental Health (57)  ·  Yale University (53)  ·  VA Office of Research and Development (51)  ·  National Institute of Mental Health (NIMH) (36)  ·  Massachusetts General Hospital (35)  ·  Central South University (34)  ·  Eli Lilly and Company (33)  ·  National Taiwan University Hospital (33)  ·  Hôpital le Vinatier (31)  ·  University of California, San Diego (30)

Countries

United States (1444)  ·  China (241)  ·  France (237)  ·  Canada (190)  ·  Taiwan (179)  ·  Germany (174)  ·  Spain (155)  ·  Israel (113)  ·  South Korea (111)  ·  Russia (110)  ·  United Kingdom (110)  ·  Turkey (Türkiye) (93)  ·  Ukraine (89)  ·  Romania (83)  ·  Bulgaria (79)

Top investigators

Benedicto Crespo-Facorro, Professor (13)  ·  Hai-Gwo Hwu, Professor (12)

Results publications

PMID 28433500, PMID 33539561, PMID 33854317, PMID 34091867, PMID 38958149, PMID 37142273, PMID 20537128, PMID 20537130, PMID 24423017, PMID 25890643, PMID 22198451, PMID 24955752, PMID 28350572, PMID 32476658, PMID 34689733, PMID 34751928, PMID 36369028, PMID 38085556, PMID 39144777, PMID 41130742, PMID 42393474, PMID 18466043, PMID 20840778, PMID 21155708, PMID 22935168, PMID 26493637, PMID 27188270, PMID 27743205, PMID 27816567, PMID 28117049, PMID 28318835, PMID 28640988, PMID 28692485, PMID 30420252, PMID 30470662, PMID 32336984, PMID 32606705, PMID 32840872, PMID 33861952, PMID 33914891, PMID 34004383, PMID 34901863, PMID 35235720, PMID 36418846, PMID 36711165, PMID 36772948, PMID 36883881, PMID 37230961, PMID 37756123, PMID 37777515

NIH funding

2019 (11), 2017 (9), 2009 (8), 2016 (8), 2015 (7), 2018 (7), 2025 (7), 2008 (6), 2023 (4), N01MH090001 (4), P50MH082999 (4), P50MH119569 (4), 2004 (3), D43TW009114 (3), N01MH90001 (3)